The average realised pay for the chief executive of an ASX100 company in the 2023 financial year was 50 times what an average Australian worker earned.
Sleep treatments giant ResMed has been splashing cash on projects for growth as the sector spends up to secure post-pandemic growth.
The sleep treatments maker hopes to make its way through a global economic slowdown unscathed despite many of the markets it sells into facing serious headwinds.
The Australian sleep apnoea treatments maker has made two recent acquisitions focused on digital health.
Ventilator and sleep products maker ResMed has been on a rollercoaster for two years. Are its shares a good buy after their recent price falls?
The medtech giant was forced to shave $US100 million off its revenue forecasts for capitalising on a competitor’s recall,with the stock falling 5 per cent.
Sleep treatment giant ResMed says rising freight costs and semiconductor chip shortages are curbing its ability to meet surging global demand for its devices.
No debt and a focus on innovation has allowed software medical imaging company,Pro Medicus,to expand globally,turning its founders into billionaires.
Supply chain issues are lingering but ResMed boss Mick Farrell says the sleep treatment maker can secure long-term market share after a competitor’s major recall.
New York University alleges Resmed has illegally used the university’s science to create the AirSense10 machine,one of its best-selling products.
The US-based chief executive of one of Australia’s largest medtechs says the country must focus on both procuring doses and pitching their use to the public.